HomeAI · summaries
Storia in 2 fonti
Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push
The $10.5 billion partnership announced by Chinese innovative biotech Innovent Biologics and US pharmaceutical giant Pfizer in late May highlights an emerging shift in cross-border biotech dealmaking, with some Chinese drug developers moving beyond traditional out-licensing arrangements toward partnerships that include joint development and commercialization.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s onc | Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics…
- ·
global.chinadaily.com.cn
Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push
The $10.5 billion partnership announced by Chinese innovative biotech Innovent Biologics and US pharmaceutical giant Pfizer in late May highlights an emerging shift in…